Institutional investors purchased a net $668.5 thousand shares of CYCC during the quarter ended September 2016. This may signal that the smart money is gaining interest in this company as the 33.88% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
TANG CAPITAL MANAGEMENT LLC Bought 359.9 Thousand shares of Cyclacel Pharmaceuticals ...
ISZO CAPITAL MANAGEMENT LP Bought 169.5 Thousand shares of Cyclacel Pharmaceuticals ...